Apple and Johnson & Johnson collaborating on heart research project - MarketWatch

Johnson & Johnson's JNJ, +0.39% Janssen Pharmaceuticals Inc. is collaborating on a multi-year research study with Apple Inc. AAPL, -0.84% to look at improving outcomes for patients with atrial fibrillation, the companies announced Thursday. The study will investigate whether a heart health app by Johnson & Johnson, combined with Apple Watch's irregular rhythm notifications and ECG app, can accelerate diagnosis and improve outcomes for people with atrial fibrillation. Atrial fibrillation is a condition that affects 33 million people worldwide and can lead to blood clots, stroke and heart failure. The study will be based in the U.S., the companies said, and subjects will be individuals 65 years or older. Shares of Apple were down 0.5% in premarket trade Thursday and have fallen 1.8% in the year to date through Wednesday. Shares of Johnson & Johnson have fallen 0.8%, while the S&P 500 SPX, -0.04% has gained 4.4% and the Dow Jones Industrial Average DJIA, -0.21% has gained 3.8%.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Let's block ads! (Why?)